Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $259,594,000 | $227,934,000 | $208,859,000 | $165,615,000 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Cost of Goods Sold | $164,865,000 | $146,551,000 | $136,145,000 | $95,429,000 |
| Gross Profit | $94,729,000 | $81,383,000 | $72,714,000 | $70,186,000 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| R&D Expenses | $0 | $13,242,000 | $15,265,000 | $11,488,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $71,486,000 | $50,493,000 | $51,934,000 | $40,162,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,000 | $1,000 | $0 | -$670,000 |
| Operating Expenses | $71,487,000 | $63,736,000 | $67,199,000 | $50,980,000 |
| Operating Income | $23,242,000 | $17,647,000 | $5,514,000 | $19,205,000 |
| % Margin | 9% | 7.7% | 2.6% | 11.6% |
| Other Income/Exp. Net | $3,088,000 | $6,812,000 | -$909,000 | $3,040,000 |
| Pre-Tax Income | $26,330,000 | $24,459,000 | $4,605,000 | $22,246,000 |
| Tax Expense | $7,343,000 | $8,286,000 | $2,404,000 | $6,331,000 |
| Net Income | $18,986,000 | $16,173,000 | $2,201,000 | $15,914,000 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS | 385.71 | 328.59 | 44.72 | 323.35 |
| % Growth | 17.4% | 634.8% | -86.2% | – |
| EPS Diluted | 385.71 | 328.59 | 44.72 | 316.19 |
| Weighted Avg Shares Out | 49,225 | 49,219 | 49,222 | 49,216 |
| Weighted Avg Shares Out Dil | 49,225 | 49,219 | 50,342 | 50,325 |
| Supplemental Information | – | – | – | – |
| Interest Income | $221,000 | $97,000 | $17,000 | $8,000 |
| Interest Expense | $1,627,000 | $947,000 | $635,000 | $230,000 |
| Depreciation & Amortization | $20,099,000 | $17,888,000 | $19,409,000 | $10,954,000 |
| EBITDA | $48,056,000 | $43,294,000 | $24,924,000 | $29,492,000 |
| % Margin | 18.5% | 19% | 11.9% | 17.8% |